MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Study Summary

This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.

Conditions

Plexiform Neurofibroma Neurofibromatosis Type 1 (NF1)

Interventions / Drugs

Mirdametinib (PD-0325901) oral capsule or dispersible tablet

View on ClinicalTrials.gov ↗

Sponsor

SWTX

SpringWorks Therapeutics

Rare Oncology

D40/100

Study Details

Enrollment114 participants

Primary Completion—

Lead SponsorSpringWorks Therapeutics, Inc.

Data Retrieved2026-04-11 04:28:29.597242+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.